摘要
目的观察六味能消胶囊联合非诺贝特和辛伐他汀治疗混合性高脂血症的临床疗效。方法选取2015年7月—2016年6月在澄迈县人民医院就诊的混合性高脂血症患者106例,随机分为对照组和治疗组,每组各53例。对照组口服非诺贝特胶囊,200 mg/次,1次/d;同时晚睡前口服辛伐他汀片,20 mg/次,1次/d。治疗组在对照组的基础上口服六味能消胶囊,1粒/次,3次/d。两组均连续治疗8周。比较两组治疗前后临床疗效和血脂水平。结果治疗后,对照组和治疗组的总有效率分别为79.24%、90.57%,两组总有效率比较差异有统计学意义(P<0.05)。治疗后,两组患者三酰甘油(TG)、总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)水平显著下降,高密度脂蛋白胆固醇(HDL-C)水平明显升高,同组治疗前后差异具有统计学意义(P<0.05);且治疗组上述血脂指标水平改善优于对照组,两组比较差异具有统计学意义(P<0.05)。结论六味能消胶囊联合非诺贝特和辛伐他汀治疗混合性高脂血症临床疗效确切,可显著降低血脂水平,具有一定的临床推广应用价值。
Objective To observe the clinical effect of Liuwei Nengxiao Capsules combined with fenofibrate and simvastatin in treatment of mixed hyperlipidemia.Methods Patients (106 cases) with mixed hyperlipidemia in Chengmai County People&#39;s Hospital from July 2015 to June 2016 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group werepoadministered with Fenofibrate Capsules, 200 mg/time, once daily. And they were alsopo administered with Simvastatin Tablets before going to bed, 20 mg/time, once daily. Patients in the treatment group were poadministered with Liuwei Nengxiao Capsules on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy and blood lipid levels in two groups were compared.Results After treatment, the clinical efficacies in the control and treatment groups were 79.24% and 90.57% respectively, and there was difference between two groups (P 〈 0.05). After treatment, the TG, CHO, and LDL-C levels in two groups were significantly decreased, but the HDL-C level was significantly increased, and the difference was statistically significant in the same group (P 〈 0.05). And these blood lipid levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P 〈 0.05).Conclusion Liuwei Nengxiao Capsules combined with fenofibrate and simvastatin has an obvious clinical curative effect in treatment of mixed hyperlipidemia, can significantly decrease blood lipid levels, which has a certain clinical application value.
出处
《现代药物与临床》
CAS
2017年第4期625-627,共3页
Drugs & Clinic